Cell surface CH60 is also described to act as an agonist of various receptors, such as α3β1 integrin on breast cancer cells (Barazi et al, 2002), TREM2 on microglia (Stefano et al, 2009), and CD18 on macrophages (Long et al, 2003). Here, ITGB2 is linked to breast carcinoma.